CSMG Technologies Subsidiary Live Tissue Connect Technology And Product Performance Will Be Presented At The Central European Congress Of Surgery

Main Category: Conferences
Also Included In: Cosmetic Medicine / Plastic Surgery;  Transplants / Organ Donations
Article Date: 26 Mar 2008 - 14:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

CSMG Technologies, Inc., (OTC BB: CTGI) a technology management company, announce its Live Tissue Connect, Inc. (LTC) subsidiary's technology will be present at Central European Congress of Surgery in Prague, Czech.

Dr. Robert Tucker M.D. PhD, of the University of Iowa, has had three clinical papers peer reviewed and accepted at a surgical congress. Dr. Tucker will be presenting these three papers, which describe his results with Live Tissue Connect's technology and product performance, at the Central European Congress of Surgery (CECS), April 23rd to 26th, 2008, in Prague, Czech Republic.

The focus of this Congress is the developing fields of surgery, evidence-based medicine and new technologies. Many international experts have been invited to share their knowledge and experience in surgery, oncology and radiology at this congress.

Donald S. Robbins, President and CEO of CSMG Technologies, said, "It is a great privilege for LTC to have Dr. Tucker's papers selected for presentation at the CECS Congress. This our first opportunity to publicly unveil the RF sealing results that are obtainable with LTC's products, and to compare such to leading RF sealing medical device companies that already have a market presence."

Frank D'Amelio, Live Tissue Connect's President, commented, "LTC will have a booth and will be exhibiting at this important meeting. This will allow us the opportunity to discuss LTC's technology and product performance with leading physicians and European distributors."

CSMG Technologies owns the technology and exclusive world rights to the live tissue bonding device through Live Tissue Connect, Inc., a subsidiary corporation formed for the development and exploitation of the platform technology. European CE Mark has been received on the electrosurgical generator and United States FDA 510K clearance documentation has been filed for the duct and vessel sealing product. The duct and vessel sealing electrosurgical generator and associated hand instruments are currently being produced in production quantities.

Surgeons at 27 Ukrainian hospitals and clinics are using the tissue welding/bonding technology in clinical trials. They have completed more than 10,000 human surgeries including more than 80 types of open and laparoscopic surgical procedures, establishing that the technology is universal in its ability to repair soft biological tissue.

U.S., Australian, Canadian, Ukraine and European Union patents have been issued, and additional U.S. and foreign patents are pending. LTC currently owns a total of 44 patents issued or pending.

About CSMG Technologies, Inc.

CSMG Technologies is a technology management company that finances, owns, develops, licenses and markets innovative advanced technologies and business opportunities created in the Ukraine through a network of scientific institutes and private organizations. CSMG is focused on two primary subsidiaries, Live Tissue Connect, Inc. and landfill gas processing.

For further information on CSMG Technologies and its various subsidiaries, please visit our website at http://www.csmgtechinternational.com.

Sign up to receive CSMG Technologies automated email press releases and other notifications: Please go to here and fill-in information.

Safe Harbor Statement

This press release may contain forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934 as amended (the Exchange Act), including all statements that are not statements of historical fact regarding the intent, belief or current expectations of the company, its directors or its officers with respect to, among other things: (i) the company's financing plans; (ii) trends affecting the company's financial condition or results of operations; (iii) the company's growth strategy and operating strategy; and (iv) the declaration and payment of dividends. The words "may," "would," "will," "expect," "estimate," "anticipate," "believe," "intend" and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the company's ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors.

CSMG Technologies